Vivli company information, Employees & Contact Information

AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial Nature

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study ScienceDirect.com

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial Nature

Access to Patient-Level Clinical Study Data UCB

European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study Frontiers

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial | Journal of Clinical Oncology ASCO Publications

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR -mutated stage IB–IIIA non-small-cell lung cancer Nature

Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants | Circulation American Heart Association Journals

Investigating the evolution and predicting the future outlook of antimicrobial resistance in sub-saharan Africa using phenotypic data for Klebsiella pneumoniae: a 12-year analysis BMC Microbiology

Ontology-based categorization of clinical studies by their conditions ScienceDirect.com

F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on ASCO Publications

Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors Frontiers

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort Nature

Towards a survival risk prediction model for metastatic NSCLC patients on durvalumab using whole-lung CT radiomics Frontiers

-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study Nature

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial Nature

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial Nature

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data Nature

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer Nature

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab Frontiers

Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity Frontiers

Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer Nature

Prediction of antibiotic resistance from antibiotic susceptibility testing results from surveillance data using machine learning Nature

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial American Heart Association Journals

Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development Frontiers

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes Frontiers

Investigating the feasibility and potential of combining industry AMR monitoring systems: a comparison with WHO GLASS medRxiv

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing AAP

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants Nature

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma ScienceDirect.com

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection Frontiers

Innovative Global Data-Sharing Platform Vivli Launches Cochrane

Moving Data Sharing Forward: The Launch of the Vivli Platform National Academy of Medicine

SABA prescriptions and asthma management practices in Singapore: results from a cross-sectional, observational SABINA III study BMJ Open

Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma? Dove Medical Press

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population | npj Precision Oncology Nature

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans PNAS

The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa Frontiers

Real-World Progression-Free Survival as an Endpoint in Advanced Non-Small-Cell Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Data Derived From Electronic Health Records medRxiv

Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19 medRxiv

Discernment of Mediator and Outcome Measurement in the PACE trial medRxiv